Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 608

1.

Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients.

Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O.

Nephron. 1997;77(2):176-85.

PMID:
9346384
[PubMed - indexed for MEDLINE]
2.

Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients.

Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK.

Nephrol Dial Transplant. 2001 Feb;16(2):307-12.

PMID:
11158405
[PubMed - indexed for MEDLINE]
Free Article
3.

Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients.

Roth D, Smith RD, Schulman G, Steinman TI, Hatch FE, Rudnick MR, Sloand JA, Freedman BI, Williams WW Jr, Shadur CA, et al.

Am J Kidney Dis. 1994 Nov;24(5):777-84.

PMID:
7977319
[PubMed - indexed for MEDLINE]
4.

Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease.

Dean BB, Dylan M, Gano A Jr, Knight K, Ofman JJ, Levine BS.

Curr Med Res Opin. 2005 Jul;21(7):981-7.

PMID:
16004664
[PubMed - indexed for MEDLINE]
5.

r.hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline.

Tapolyai M, Kadomatsu S, Perera-Chong M.

BMC Nephrol. 2003 Jun 17;4:3.

PMID:
12809563
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

The cardiovascular and hemodynamic effects of erythropoietin in chronic renal failure.

Singh NP, Chandrashekhar, Nair M, Anuradha S, Kohli R, Agarwal SK.

J Assoc Physicians India. 2000 Mar;48(3):301-6.

PMID:
11229114
[PubMed - indexed for MEDLINE]
7.

Factor deficiency in the anemia of renal transplant patients with grade III-IV chronic kidney disease: baseline results of the ARES Study.

Gentil MA, Pérez-Valdivia MA, López-Mendoza M, Ortega F, Arias M, Gómez-Alamillo C, Campistol JM; ARES Study Group.

Transplant Proc. 2008 Nov;40(9):2922-4. doi: 10.1016/j.transproceed.2008.08.083.

PMID:
19010148
[PubMed - indexed for MEDLINE]
8.

Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: effect of long-term therapy with erythropoietin.

Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD.

Kidney Int. 2005 Jul;68(1):246-55.

PMID:
15954914
[PubMed - indexed for MEDLINE]
9.

Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study.

Albertazzi A, Di Liberato L, Daniele F, Battistel V, Colombi L.

Int J Artif Organs. 1998 Jan;21(1):12-8.

PMID:
9554820
[PubMed - indexed for MEDLINE]
10.

Effect of recombinant human erythropoietin on renal function in humans.

Lim VS, Fangman J, Flanigan MJ, DeGowin RL, Abels RT.

Kidney Int. 1990 Jan;37(1):131-6.

PMID:
2299799
[PubMed - indexed for MEDLINE]
11.

The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.

Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, Baruch R, Yachnin T, Steinbruch S, Iaina A.

Clin Nephrol. 2001 Mar;55(3):212-9.

PMID:
11316241
[PubMed - indexed for MEDLINE]
12.

Recombinant human erythropoietin treatment of anemia in renal transplant patients.

Lezaic V, Djukanovic L, Pavlovic-Kentera V.

Ren Fail. 1995 Nov;17(6):705-14.

PMID:
8771243
[PubMed - indexed for MEDLINE]
13.

Renal function in predialysis children with chronic renal failure treated with erythropoietin.

Krmar RT, Gretz N, Klare B, Wühl E, Schärer K.

Pediatr Nephrol. 1997 Feb;11(1):69-73.

PMID:
9035175
[PubMed - indexed for MEDLINE]
14.

Metabolic effects of keto acid--amino acid supplementation in patients with chronic renal insufficiency receiving a low-protein diet and recombinant human erythropoietin--a randomized controlled trial.

Teplan V, Schück O, Votruba M, Poledne R, Kazdová L, Skibová J, Malý J.

Wien Klin Wochenschr. 2001 Sep 17;113(17-18):661-9.

PMID:
11603100
[PubMed - indexed for MEDLINE]
15.

Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.

Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.

J Hypertens. 2000 Jan;18(1):89-95.

PMID:
10678548
[PubMed - indexed for MEDLINE]
16.

[Comparative study of the efficacy of different regimens of intermittent subcutaneous dosing of erythropoietin beta in treatment of renal anemia in chronic dialysis patients].

Nesić V, Ostrić V, Kovacević Z, Dimković N, Curić S, Lazarević M, Ratković M, Bogdanović J, Jelacić R.

Med Pregl. 2005 May-Jun;58(5-6):279-85. Serbian.

PMID:
16526235
[PubMed - indexed for MEDLINE]
17.

Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance?

Cruz DN, Perazella MA, Abu-Alfa AK, Mahnensmith RL.

Am J Kidney Dis. 1996 Oct;28(4):535-40.

PMID:
8840943
[PubMed - indexed for MEDLINE]
18.
19.

Effect of erythropoietin on urinary liver-type fatty-acid-binding protein in patients with chronic renal failure and anemia.

Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H.

Am J Nephrol. 2006;26(3):276-80. Epub 2006 Jun 13.

PMID:
16772708
[PubMed - indexed for MEDLINE]
20.

Enhanced metabolic effect of erythropoietin and keto acids in CRF patients on low-protein diet: Czech multicenter study.

Teplan V, Schück O, Knotek A, Hajný J, Horácková M, Kvapil M; Czech multicenter study.

Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S26-30.

PMID:
12612947
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk